linjc16/ctgov huggingface dataset:
Epidemiology Study of Keloid

Study Overview
=================
Brief Summary
-----------------
Although keloid is a very common condition; there are no statistics as to its true incidence and prevalence, neither in United States, nor elsewhere in the world. This trial intends to capture epidemiological data about this disease in a large population sample.

Detailed Description
-----------------
The purpose of current trial is to establish a robust database of incidence and prevalence of keloid, as well as prevalence of familial keloid, in various ethnic groups. Study sample size is 100,000 random individuals who will fill out either a web survery or a paper questionnaire.

Official Title
-----------------
Epidemiology Study of Keloid

Conditions
-----------------
Keloid

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Informed consent Age above 18 to answer the survey questions Parents shall respond on behalf of their minor children Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Random Populations<br>The aim of this study is to determine the prevalence and incidence of keloid in large populations. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of various clinical findings will be determined at the end of Survey. | This will be a prospective online and paper based survey with an estimated 100,000 responders participating in two years. Statistics will be descriptive. The prevalence of various clinical findings will be determined at the end of Survey. Findings will be correlated with the source of the data, online, or paper questionnaire, as well as the locations where the paper questionnaires surveys were placed. | Two Years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Keloid
Study of the Prognostic Role of Gene Polymorphism in the Development of B-cell Leukemias and Lymphomas in Children of Kazakh Nationality

Study Overview
=================
Brief Summary
-----------------
To search for a genetic marker of B-cell leukemias and lymphomas in children of Kazakh nationality, a single nucleotide polymorphism (SNP) analysis of DNA obtained from the peripheral blood of patients with B-cell leukemias and lymphomas in children of Kazakh nationality and normal control will be performed.

Official Title
-----------------
Preventive and Personalized Medicine (2021-2023)

Conditions
-----------------
B Cell Leukemia, Lymphoma

Intervention / Treatment
-----------------
* Genetic: SNP analysis of the DNA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ethnicity - Kazakhs in at least three generations active disease or a history of B-line ALL or B-NHL, established on the basis of morphological, cytochemical, immunophenotypic or immunohistochemical research methods with confirmation of the fact of the disease in medical documentation Signed voluntary informed consent of the legal representative to participate in the project Exclusion Criteria: Children suffering from other types of malignant neoplasms Children with B-linear leukemia and lymphomas with concomitant specified genetic and chromosomal diseases Children of non-Kazakh nationality Absence of signed informed consent or informed refusal of the legal representative to participate in the study before starting therapy

Ages Eligible for Study
-----------------
Minimum Age: 0 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental group:<br>children with B-cell leukemia and lymphoma of Kazakhstani nationality | Genetic: SNP analysis of the DNA<br>* SNP analysis of the DNA obtained from peripheral blood sample<br>* Other names: SNP analysis of the DNA obtained from peripheral blood sample;|
| Control group<br>children without B-cell leukemia and lymphoma of Kazakhstani nationality | Genetic: SNP analysis of the DNA<br>* SNP analysis of the DNA obtained from peripheral blood sample<br>* Other names: SNP analysis of the DNA obtained from peripheral blood sample;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Associated with B-cell lymphoma and B-cell acute lymphoblastic leukemia | Genotype frequency of SNP in the study genes of participants and control participants. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SNP
Influence of Vibroacoustic Therapy Modes on the Course of Coronavirus Infection

Study Overview
=================
Brief Summary
-----------------
Assessment of the dynamics of changes in physical, instrumental and laboratory parameters in patients with identified coronavirus infection complicated by acute respiratory failure included in the study in accordance with the inclusion criteria, and comparison of the results with the control group, study of the effect of modes when using vibroacoustic lung therapy.

Official Title
-----------------
The Effect of Various Modes of Vibroacoustic Therapy on the Course of Coronavirus Infection Complicated by Acute Respiratory Failure.

Conditions
-----------------
COVID-19, Acute Respiratory Failure, Vibration; Exposure

Intervention / Treatment
-----------------
* Device: Vibrolung


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adults P/F less 300 torr COVID-19 Virus Infection Exclusion Criteria: children acute stroke acute coronary syndrome DVT implanted pacemaker rib fracture infection on chest

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: SaO2 (oxygen status)<br>Measurment 4 times per day, ABA (acid-bases analyses) | Device: Vibrolung<br>* Vibroacoustic respiratory therapy<br>|
| Active Comparator: PaO2/FiO2 (respiratory index)<br>Measurment 4 times per day, ABA (acid-bases analyses) | Device: Vibrolung<br>* Vibroacoustic respiratory therapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of time spent on ventilation | Changing of the time spent by patients on mechanical ventilation | 1-2 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute Respiratory Failure, Vibration; Exposure, COVID-19
Respiratory Tract Infections and Prescription Drugs in Children and in Pregnancy

Study Overview
=================
Brief Summary
-----------------
The main objective is to investigate the incidence of Respiratory Tract Infections (RTIs) and antibiotic prescriptions in children and during pregnancy, the different drugs chosen by their doctors according to diagnosis, and compliance by patients. Further to investigate the possible effect of antibiotic use during pregnancy on RTIs and antibiotics and respiratory drug prescriptions in children the first two years after birth. Specific study objectives: RTIs and antibiotic prescriptions in pre-school children Frequency of diagnoses and antibiotic prescriptions The proportion of broad spectrum antibiotics chosen Prescription patterns and treatment compliance during pregnancy Incidence of diagnoses, compared with not pregnant patients Choice of antibiotics in RTIs Prescription collection from pharmacies Antibiotics and respiratory medication in children aged 0-2 yrs Compare prevalence in children of mothers with frequent RTIs/antibiotic prescriptions during pregnancy and prevalence in children of mothers with few or no consultations during pregnancy Incidence of wheezing and asthma diagnoses and incidence og respiratory prescription drugs when the mother has received antibiotics in pregnancy

Official Title
-----------------
Respiratory Tract Infections and Prescription Drugs in Children and in Pregnancy - a Study From Norwegian General Practice

Conditions
-----------------
Respiratory Tract Diagnoses (ICPC-2), Prescriptions of Antibiotics by General Practitioners, Prescriptions of ATC J01 and R Drugs in Participants

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Contact with general practitioner in the time of registration Exclusion Criteria: Men (except children aged 0-2 yrs) Women in ages 2-14 and above 60 yrs

Ages Eligible for Study
-----------------
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Children aged 0-2 yrs<br> | |
| Women aged 15-60 yrs<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
antibiotics, prescriptions, pregnancy, children
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma

Study Overview
=================
Brief Summary
-----------------
The objective of this pilot study is to evaluate the safety, tolerability and activity of the monoclonal antibody CT-011 administered intravenously to patients with Primary Hepatocellular Carcinoma.

Official Title
-----------------
Phase I/II Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma

Conditions
-----------------
Primary Hepatocellular Carcinoma

Intervention / Treatment
-----------------
* Drug: CT-011


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects aged 18 years and above, both genders. Histologically or cytologically confirmed Primary Hepatocellular Carcinoma (HCC) No fibrolamellar subtype HCC Not eligible for any other systemic anti-neoplastic treatment approved for HCC Not eligible for Transarterial chemoembolization (TACE ). No more than 1 prior systemic therapy. Previous TACE or Radiofrequency ablation (RFA) that were used for HCC, are permitted. Not a candidate for curative surgical resection or liver transplantation Measurable disease defined by the identification at least 1 measurable lesion by MRI using RECIST criteria. Tumor in area of TACE or RFA must be enlarging post-procedure to be considered measurable disease. Alpha-fetoprotein (AFP) greater than the upper limit of normal (ULN) Child's Pugh classification A ECOG performance status 0-1 Exclusion Criteria: Patients progressing to liver failure. No core biopsy within the past 7 days Patients who are eligible for Transarterial Chemoembolization (TACE) Patients on concurrent anti-neoplastic therapy (including interferon) Patients who have received any systemic anti-neoplastic therapy not approved for the treatment of HCC. Patients on concurrent steroids, other than those allowed for routine antiemetics, or inhaled steroids Presence of metastasis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CT-011<br> | Drug: CT-011<br>* CT-011<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the safety and tolerability of CT-011 in patients with Primary Hepatocellular Carcinoma |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Primary Hepatocellular Carcinoma
Validation Study of a New Digital Treatment Test

Study Overview
=================
Brief Summary
-----------------
Oculomotor behavior and cognitive processing of visual information are intimately connected. AD patients show ocular movement problems. Oculomotor deficits are broad consisting mainly of different saccade metrics, altered pupil responses. and smaller and irregular eye vergence movements. Here we test an interactive eye-tracking game to improve eye motion control and thereby training cognitive behavior

Official Title
-----------------
Validation Study of a New Digital Treatment Test Based on Interactive Video Games for Alzheimer's Disease

Conditions
-----------------
Alzheimer Disease, MCI

Intervention / Treatment
-----------------
* Other: BGaze therapy Alzheimer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1) Clinical diagnosis of MCI or AD Exclusion Criteria: Severe cognitive deterioration History of neurological disease with clinically relevant impact on cognition Severe psychiatric disorder Incidental structural brain findings with impact on cognitive impairment Presence of relevant visual problems

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment<br> | Other: BGaze therapy Alzheimer<br>* BGaze Therapy is an interactive eye tracking game<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MoCA | Measure changes in MoCA | immediately after the intervention | 
| MMSE | Measure changes in MMSE | immediately after the intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CANTAB | Measure changes in CANTAB tests | immediately after the intervention |
A Quality of Life Study re Management of Malignant Pleural Effusions

Study Overview
=================
Brief Summary
-----------------
There is much data in the literature regarding optimal treatment approaches for malignant pleural effusions as assessed by patient outcomes. However, data on quality of life and satisfaction with treatment from the patient's perspective is not available.

Detailed Description
-----------------
This study will compare various treatment strategies in the management of malignant pleural effusions with respect to: Primary endpoint: the successful palliation of symptomatic pleural effusions as assessed by the London Chest Activity of Daily Living Scale (LCADLS) Secondary endpoints: i) impact of treatment on patient quality of life as assessed by the Functional Assessment of Chronic Illness Therapy - Palliative patient (FACIT-PAL) questionnaire ii) Assessment of patient satisfaction with treatment received via Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction (FACIT-TS) questionnaire iii)Pleurodesis success rates assessed by 2 and 6-week effusion control rates on CXR iv) Requirement of further hospitalizations or procedures for the treatment of recurrent effusions v) Comparison of morbidity and mortality rates for differing treatment approaches vi) comparison of cost in a Canadian health care setting for differing treatment approaches

Official Title
-----------------
A Prospective Study of Patient Centered Outcomes in the Management of Malignant Pleural Effusions

Conditions
-----------------
Malignant Pleural Effusions

Intervention / Treatment
-----------------
* Behavioral: LCADLS, FACIT-PAL, FACIT-TS questionnaires


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: symptomatic pleural effusion history of malignant disease age greater that 18 years consent to participate in study Exclusion Criteria: significant ipsilateral endobronchial disease prior ipsilateral, intra-pleural therapy, as defined by: prior chest tube placement for effusion, prior attempt at chemical/surgical pleurodesis, prior surgical pleurectomy active pulmonary or pleural infection granulocytes < 1500/mm3, platelets < 50,000/mm3 systemic chemotherapy within 2 weeks allergy to talc

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: LCADLS, FACIT-PAL, FACIT-TS questionnaires|LCADLS, FACIT-PAL, FACIT-TS questionnaires|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the successful palliation of symptomatic pleural effusions as assessed by the London Chest Activity of Daily Living Scale (LCADLS) |  | discharge, 2 wks and 6 wks |
Ganglionated Plexi Ablation Combined With Pulmonary Vein Isolation

Study Overview
=================
Brief Summary
-----------------
The investigators have conducted a prospective, double-blind, randomized study to assess the comparative safety and efficacy of two different ablation strategies, PVI plus linear lesions (LL) versus PVI plus GP ablation, in patients with persistent or longstanding persistent AF. Results were assessed after follow-up of at least 3 years with the use of an implanted monitoring device (IMD).

Official Title
-----------------
Ganglionated Plexi Ablation vs Linear Ablation in Patients Undergoing Pulmonary Vein Isolation for Persistent/Longstanding Persistent Atrial Fibrillation: A Randomized Comparison

Conditions
-----------------
Persistent Atrial Fibrillation

Intervention / Treatment
-----------------
* Procedure: Pulmonary vein isolation
* Procedure: Ganglionated plexi ablation
* Procedure: Linear Lesion Ablation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Persistent and longstanding persistent AF Exclusion Criteria: congestive heart failure LV ejection fraction < 35% left atrial diameter > 60 mm

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: PVI+LL<br>Circumferential PVI was accomplished and then additional ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the LA between the two superior PVs (roof). Finally, patients underwent cavo-tricuspid isthmus ablation in the right atrium. | Procedure: Pulmonary vein isolation<br> <br> Procedure: Linear Lesion Ablation<br> <br> |
| Active Comparator: PVI+GP<br>To accomplish ganglionated plexi ablation, LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter high-frequency stimulation (HFS). Rectangular electrical stimuli were delivered at a frequency of 20-50 Hz, output amplitude 15 V and pulse duration of 10 ms, for 5 sec (Stimulator B-53, Biotok Inc, Russia). | Procedure: Pulmonary vein isolation<br> <br> Procedure: Ganglionated plexi ablation<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| freedom of atrial tachyarrhythmia, including AF and atrial flutter/tachycardia |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Arrhythmias, Ablation
The Influence of Cognitive Status on Walking Abilities After Femoral Neck Fracture

Study Overview
=================
Brief Summary
-----------------
Introduction: Femoral neck fracture is a devastating injury with serious medical and social consequences. One third of these patients have some degree of impaired cognitive status. Despite of this, a high proportion of hip fracture trials exclude patients with cognitive impairment. The investigators aimed to evaluate whether moderate to severe cognitive impairment could predict walking ability, quality of life, functional outcome, reoperations and mortality in elderly patients treated with hemiarthroplasty. Methods: This cohort study included a consecutive series of 188 patients treated with hemiarthroplasty for an displaced femoral neck fracture. Patient were assessed for estimated preoperative and 1 year postoperatively with regard to walking abilities, cognitive status, quality of life with EQ-5D and hip function with Harris hip score.

Official Title
-----------------
The Influence of Cognitive Status on Walking Abilities After Hemiarthroplasty for Femoral Neck Fracture: a Prospective Cohort Study

Conditions
-----------------
Hip Fracture, Femoral Neck Fracture

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 65 year or above Displaced femoral neck fracture Treated with a hemiarthroplasty Exclusion Criteria: Pathological fractures Bilateral femoral neck fractures Bed-ridden patients.

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control group<br>Pfeiffer test 6 or above. No or mild cognitive impairment | |
| Cognitivt impaired<br>Pfeiffer test less than 6. Moderate to severe cognitive impairment. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Walking abilities | At follow-up patients report whether they are walking or not by questionnaire | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Harris hip score |  | 2 years | 
| EQ-5D |  | 2 years | 
| Reoperation |  | 2 years | 
| Mortality |  | 2 years |